指南与共识炎症性肠病

克罗恩病抗纤维化药物开发终点的确定

Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohn's Disease.
指南 / 共识 · Gastroenterology · 2018-03-28

国际炎症性肠病研究组织通过系统综述和两轮德尔菲法在线调查,由来自5个地区的48名炎症性肠病专家对36个候选终点进行评估,最终确定13个核心终点可用于克罗恩病抗纤维化药物的临床试验疗效评估。

要点

  • 13个核心终点被评定为关键,包括完全临床缓解、长期疗效、持续临床获益等。
  • 专家共识一致度高。
  • 仍需研究明确这些终点的测量方法并验证测量工具。

核心结论

  • 国际炎症性肠病研究组织成员就一套可用于评估克罗恩病患者临床试验中抗纤维化药物的终点达成专家共识。
  • 仍需研究明确这些结局的测量方法并验证测量工具。

研究设计与样本

  • 系统综述用于识别评估纤维狭窄型克罗恩病活动度和治疗反应的临床、放射学、生化、内镜及复合终点,并确定其操作特性。
  • 国际炎症性肠病研究组织专家组通过两轮德尔菲法在线调查进行共识流程,以确定临床试验中最佳终点。
  • 来自5个地区(北美、欧洲、中东、亚太和拉丁美洲)的48名炎症性肠病专家参与了德尔菲共识流程。

主要发现

  • 共选择并评估了36个与肠道纤维化可能相关的终点。
  • 13个核心终点被评定为关键:完全临床缓解、长期疗效、持续临床获益、治疗失败、放射学缓解、正常生活质量、无激素临床缓解、治疗失败、深度缓解、完全无梗阻症状、无病生存、肠道损伤进展和无残疾。

关键数值与推荐

  • 13个核心终点被评定为关键,专家间一致度高。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 仍需研究明确这些结局的测量方法并验证测量工具。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Intestinal fibrosis is a challenge to management of patients with Crohn's disease (CD); there is an urgent need to expedite development of antifibrosis drugs for this disease. The International Organization for the Study of Inflammatory Bowel Disease (IOIBD) aimed to identify a set of endpoints that can be used to determine efficacy of antifibrosis agents tested in clinical trials of patients with CD. METHODS: We conducted a systematic review to identify clinical, radiologic, biochemical, endoscopic, and composite endpoints used in assessing activity of fibrostenosing CD and response to treatment, and determined their operational properties. A panel of IOIBD experts performed a consensus process to identify the best endpoints for inclusion in clinical trials, through a 2-round, Delphi-style online survey. RESULTS: A total of 36 potentially relevant endpoints for intestinal fibrosis were selected and assessed. Forty-eight physicians with expertise in inflammatory bowel disease, from 5 regions (North America, Europe, Middle East, Asia/Pacific, and Latin America), participated in the Delphi consensus process. A core set of 13 endpoints (complete clinical response, long-term efficacy, sustained clinical benefit, treatment failure, radiological remission, normal quality of life, clinical remission without steroids, therapeutic failure, deep remission, complete absence of occlusive symptoms, symptom-free survival, bowel damage progression, and no disability) were rated as critical. Agreement was high among the experts. CONCLUSIONS: Members of the IOIBD reached expert consensus on a set of endpoints that can be used to assess antifibrosis agents in trials of patients with CD. Studies are needed to clarify methods for measuring these outcomes and validate measurement instruments.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Danese S, Bonovas S, Lopez A, et al. Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohn's Disease. Gastroenterology. 2018. PMID: 29601825. doi:10.1053/j.gastro.2018.03.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。